I disagree with you. every biotech investor knows that FDA approval should not be taken for granted and that there are significant risks in investing in teh sector. Intermune's management screwed up, not the FDA. The FDA clearly wanted multiple trials and only one by Intermune is delivering positive data. What took management so long to correct this.... and only did it after the FDA denied teh application. Additionally, I believe INCY's pipeline is deeper.